Amendments to the Claims

The listing of claims will replace all prior versions, and listings, of claims in the application:

1. (Presently Amended) An isolated antibody, comprising either

a) ~~a~~ the light chain variable domain ~~comprising an amino acid sequence selected from the group consisting of:~~

~~i) a sequence at least 80% identical to a sequence selected from the group consisting~~ of SEQ ID NO:~~4, 6, 8, 10, 12, and 14,~~

~~ii) a sequence of at least 15 contiguous amino acids of a sequence selected from the group consisting of SEQ ID NO:4, 6, 8, 10, 12, and 14,~~

~~iii) a sequence that is encoded by a nucleotide sequence that is at least 80% identical to a nucleotide sequence selected from the group consisting of SEQ ID NO:3, 5, 7, 9, 11, and 13, and~~

~~iv) a sequence that is encoded by a nucleotide sequence that hybridizes under moderately stringent conditions to the complement of a nucleotide sequence selected from the group consisting of SEQ ID NO:3, 5, 7, 9, 11, and 13,~~

or

b) ~~a~~ the heavy chain variable domain ~~comprising an amino acid sequence selected from the group consisting of:~~

~~i) a sequence at least 80% identical to a sequence selected from the group consisting~~ of SEQ ID NO:~~16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40,~~ 42~~, 44, 46, 48, 50, 52, 54, 56, 58, 60, and 62,~~

~~ii) a sequence of at least 15 contiguous amino acids of a sequence selected from the group consisting of SEQ ID NO:16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54, 56, 58, 60, and 62,~~

~~iii) a sequence that is encoded by a nucleotide sequence that is at least 80% identical to a nucleotide sequence selected from the group consisting of SEQ ID NO:15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, 59, and 61, and~~

~~iv) a sequence that is encoded by a nucleotide sequence that hybridizes under moderately stringent conditions to the complement of a nucleotide sequence~~

~~selected from the group consisting of SEQ ID NO:15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, 59, and 61,~~

or

c) said light chain variable domain of a) and said heavy chain variable domain of b),

~~with the proviso that said antibody does not comprise both the light chain variable domain amino acid sequence of SEQ ID NO:4, SEQ ID NO:63, SEQ ID NO:65, SEQ ID NO:67, or SEQ ID NO:69, and the heavy chain variable domain amino acid sequence of SEQ ID NO:16, SEQ ID NO:64, SEQ ID NO:66, or SEQ ID NO:68,~~

~~and~~ wherein said antibody binds to the human IL-4 receptor.

2-13. (Cancelled)

14. (Presently Amended) The antibody of Claim 1, wherein said antibody ~~is~~ comprises a combination of light chain variable domain and heavy chain variable domain selected from the group of combinations consisting of ~~L1H1, L1H2, L1H3, L1H4, L1H5, L1H6, L1H7, L1H8, L1H9, L1H10, L1H11,~~ L2H1 (SEQ ID NO:6 and 16), L2H2 (SEQ ID NO:6 and 18), L2H3 (SEQ ID NO:6 and 20), L2H4 (SEQ ID NO:6 and 22), L2H5 (SEQ ID NO:6 and 24), L2H6 (SEQ ID NO:6 and 26), L2H7 (SEQ ID NO:6 and 28), L2H8 (SEQ ID NO:6 and 30), L2H9 (SEQ ID NO:6 and 32), L2H10 (SEQ ID NO:6 and 34), L2H11 (SEQ ID NO:6 and 36), L2H12 (SEQ ID NO:6 and 38), L2H13 (SEQ ID NO:6 and 40), and L2H14 (SEQ ID NO:6 and 42)~~, L3H1, L4H1, L5H1, and L6H1~~.

15. (Previously Presented) The antibody of Claim 1 wherein said antibody is a human, humanized, or chimeric antibody.

16. (Previously Presented) The antibody of Claim 1 wherein said antibody is a monoclonal antibody.

17. (Previously Presented) The antibody of Claim 1 wherein said antibody is selected from the group consisting of an IgD, IgE, IgM, IgG1, IgG2, IgG3, IgG4, and IgG4 having at least one mutation in a hinge region that alleviates a tendency to form intra-H chain disulfide bond antibody.

18 and 19. (Cancelled)

20. (Withdrawn) An isolated nucleic acid comprising either

a) a nucleotide sequence, or the complement thereof, encoding the light chain of the antibody of Claim 1(a),

or

b) a nucleotide sequence, or the complement thereof, encoding the heavy chain of the antibody of Claim 1(b),

or

c) a nucleotide sequence, or the complement thereof, encoding a polypeptide comprising an IL-4 receptor binding portion of the antibody of Claim 1,

or

d) the nucleotide sequence of a) and the nucleotide sequence of b).

21. (Withdrawn) The isolated nucleic acid of Claim 20, wherein said nucleic acid comprises at least one nucleotide sequence selected from the group consisting of SEQ ID NO:5, 7, 9, 11, 13, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, 59, and 61.

22. (Withdrawn) A vector comprising said nucleic acid of Claim 20.

23. (Withdrawn) The vector of Claim 22 wherein said vector is an expression vector.

24. (Withdrawn) An isolated cell comprising said nucleic acid of Claim 20.

25. (Withdrawn) The isolated cell of Claim 24 wherein said cell is a hybridoma.

26. (Withdrawn) The isolated cell of Claim 24 wherein said cell is a transgenic cell.

27. (Withdrawn) A method of making said antibody of Claim 1 comprising incubating a cell comprising a nucleic acid encoding the light chain of said antibody and a nucleic acid encoding the heavy chain of said antibody under conditions that allow said cell to express said light chain and said heavy chain and that allow said light chain and said heavy chain to assemble into said antibody, and isolating said antibody from said cell.

28. (Withdrawn) The method of Claim 27, wherein said cell is a hybridoma.

29. (Withdrawn) The method of Claim 27, wherein said cell is a transgenic cell.

30. (Withdrawn) A method of inhibiting an IL-4 receptor comprising contacting a cell expressing an IL-4 receptor with the antibody of Claim 1 under conditions that allow said antibody to bind to said IL-4 receptor, wherein the binding of said antibody to said IL-4 receptor inhibits signal transduction through said IL-4 receptor.

31. (Withdrawn) The method of Claim 30 wherein said cell is a human cell.

32. (Withdrawn) The method of Claim 31 wherein said human cell is in a human.

33. (Withdrawn) A method of inhibiting an IL-4 receptor comprising contacting a cell expressing IL-4 receptor alpha with the polypeptide of Claim 18 under conditions that allow said polypeptide to bind to said IL-4 receptor alpha, wherein the binding of said polypeptide to said IL-4 receptor inhibits signal transduction through said IL-4 receptor.

34. (Withdrawn) The method of Claim 33 wherein said cell is a human cell.

35. (Withdrawn) The method of Claim 34 wherein said human cell is in a human.

36. (Withdrawn) A method of treating a condition in a subject comprising administering to said subject an amount of said antibody of Claim 1 effective for treating said condition.

37. (Withdrawn) The method of Claim 36 wherein said condition is an inflammatory or cancerous condition.

38. (Withdrawn) The method of Claim 37 wherein said inflammatory or cancerous condition is an immunological condition.

39. (Withdrawn) The method of Claim 38 wherein said condition is asthma, septic arthritis, dermatitis herpetiformis, chronic idiopathic urticaria, ulcerative colitis,

scleroderma, hypertrophic scarring, Whipple's Disease, benign prostate hyperplasia, a lung disorder in which IL-4 receptor plays a role, condition in which IL-4 receptor-mediated epithelial barrier disruption plays a role, a disorder of the digestive system in which IL-4 receptor plays a role, an allergic reaction to a medication, Kawasaki disease, sickle cell disease, Churg-Strauss syndrome, Grave's disease, pre-eclampsia, Sjogren's syndrome, autoimmune lymphoproliferative syndrome, autoimmune hemolytic anemia, Barrett's esophagus, autoimmune uveitis, tuberculosis, cyctic fibrosis, allergic bronchopulmonary mycosis, chronic obstructive pulmonary disease, bleomycin-induced pneumopathy and fibrosis, radiation-induced pulmonary fibrosis, pulmonary alveolar proteinosis, adult respiratory distress syndrome, sarcoidosis, hyper IgE syndrome, idiopathic hypereosinophil syndrome, an autoimmune blistering disease, pemphigus vulgaris, bullous pemphigoid, myasthenia gravis, chronic fatigue syndrome, or nephrosis.

40. (Withdrawn) A method of treating a condition in a subject comprising administering to said subject an amount of said polypeptide of Claim 18 effective for treating said condition.

41. (Withdrawn) The method of Claim 40 wherein said condition is an inflammatory or cancerous condition.

42. (Withdrawn) The method of Claim 41 wherein said inflammatory or cancerous condition is an immunological condition.

43. (Withdrawn) The method of Claim 42 wherein said condition is asthma, septic arthritis, dermatitis herpetiformis, chronic idiopathic urticaria, ulcerative colitis, scleroderma, hypertrophic scarring, Whipple's Disease, benign prostate hyperplasia, a lung disorder in which IL-4 receptor plays a role, condition in which IL-4 receptor-mediated epithelial barrier disruption plays a role, a disorder of the digestive system in which IL-4 receptor plays a role, an allergic reaction to a medication, Kawasaki disease, sickle cell disease, Churg-Strauss syndrome, Grave's disease, pre-eclampsia, Sjogren's syndrome, autoimmune lymphoproliferative syndrome, autoimmune hemolytic anemia, Barrett's esophagus, autoimmune uveitis, tuberculosis, cyctic fibrosis, allergic bronchopulmonary mycosis, chronic obstructive pulmonary disease, bleomycin-induced pneumopathy and fibrosis, radiation-induced pulmonary fibrosis, pulmonary alveolar

proteinosis, adult respiratory distress syndrome, sarcoidosis, hyper IgE syndrome, idiopathic hypereosinophil syndrome, an autoimmune blistering disease, pemphigus vulgaris, bullous pemphigoid, myasthenia gravis, chronic fatigue syndrome, or nephrosis.

44. (Previously Presented) A pharmaceutical composition comprising said antibody of Claim 1 and an excipient, diluent, or buffer.

45-47. (Cancelled)